Efficacy and Safety of Erenumab in Preventive and Therapeutic Treatment of Patients Suffering from Migraine
Abstract
Background: Erenumab, (AMG 334) is a first fully human monoclonal antibody that targets and blocks the canonical Calcitonin Gene related peptide (CGRP) receptor approved for use in migraine. CGRP plays a very pivotal role in patho-physiology og migraine. The objective were to generate statistical evidence on the basis of existing data for erenumab in terms of efficacy and safety in various treatment regimens with different dosages.
Methods: A total of 7 RCTs following PRISMA guidelines and matching inclusion and exclusion criteria were collected of erenumab vs placebo in treatment of migraine. Studies with >50% responder rate from baseline in terms of migraine days per month at 12 week was chosen as primary clinical outcome measure. Secondary outcome chosen were mean migraine days from baseline and safety outcomes in terms of adverse events. 5.3 software was used for the calculation of Relative Risk (RR). P value less than 0.05 was considered significant.
Results: Data of 3615 patients were included.The use of Erenumab was associated with increased rates of achieving > 50% responder rate as compared with placebo. (RR= 1.591; 95% CI =1.322 to 1.915; P <0.001). Both 70mg and 140 mg of erenumab were associated with increase in responder rate. Reduction in mean migraine days was observed in erenumab as compared to placebo, (SMD= 7.348; 95% CI= 4.733 to 9.963; P <0.001). Treatment related adverse events (RR = 0.974; 95% CI = 0.901 to 1.052; P = 0.496) were not significant in…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.